Cervical Cancer Detection Kit Using Gene Methylation Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cervical cancer detection methods, such as liquid-based cytological detection and HPV detection, suffer from high false negative and false positive results due to limitations in bisulfite conversion technology, leading to inefficient screening for high-grade cervical lesions and cervical cancer.
Innovation Solution
A composition and kit utilizing FAM19A4, JAM3, and PAX1 gene methylation-specific primers and probes, along with blocking primers, to enhance detection sensitivity and specificity through multi-channel fluorescence and optimized PCR conditions, allowing for accurate recognition of methylated regions in cervical exfoliated cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If HPV detection is used for cervical cancer screening, then sensitivity is improved (about 90%), but specificity deteriorates (approximately 60.7%) due to false positive results in young women
Solution Approach 1:
The patent segments the detection approach by separating HPV detection from methylation detection, then combining their results. It divides the screening process into two independent detection systems (HPV testing and methylation testing) that can be interpreted separately or combined, allowing each system to contribute its strengths while mitigating its weaknesses through independent analysis and integrated interpretation.
Solution Approach 2:
The patent merges HPV detection with methylation detection to create a comprehensive screening system. By combining the high sensitivity of HPV detection with the high specificity of methylation detection (which targets tumor suppressor genes like PAX1, JAM3, and FAM19A4), the system achieves both high sensitivity and high specificity simultaneously, resolving the contradiction between these two parameters.
2Measurement precision
If liquid-based cytological detection is used, then detection capability is improved compared to traditional Pap smear, but false negative rate remains high (about 50%)
Solution Approach 1:
The patent replaces mechanical cytological examination with molecular detection methods. Instead of relying on visual assessment of cellular changes through microscopy, the system uses molecular markers (methylation patterns of specific genes and HPV nucleic acids) to detect cervical lesions, achieving higher detection accuracy and lower false negative rates through biochemical rather than mechanical evaluation.
Solution Approach 2:
The patent changes the detection parameters from morphological characteristics (cell appearance in Pap smears) to molecular characteristics (methylation status of specific gene regions). By detecting methylation patterns in tumor suppressor genes and HPV viral DNA, the system identifies lesions at a molecular level, improving detection capability and reducing false negatives compared to traditional cytological parameters.
3Ease of operation
If traditional Pap smear method is used, then simplicity is maintained, but sensitivity deteriorates (between 30% and 87%, sometimes lower than 20%)
Solution Approach 1:
The patent substitutes mechanical Pap smear analysis with molecular detection systems that automate and objectiveize the detection process. By using fluorescent probes and PCR-based methods to detect methylation patterns and HPV DNA, the system eliminates the subjectivity and variability inherent in manual cytological evaluation, thereby improving sensitivity while maintaining operational simplicity through standardized molecular assays.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The kit significantly improves the detection accuracy of high-grade cervical lesions and cervical cancer by minimizing false positives and negatives, achieving a specificity of 93.1% and sensitivity of 83.9%, effectively triaging high-grade lesions and reducing unnecessary referrals.
Implementation Method 1
The invention belongs to the technical field of nucleic acid in vitro diagnosis, and specifically relates to a composition and a kit for applying specific gene methylation markers to early detection of high-grade cervical lesions and cervical cancer
Implementation Method 2
A composition and kit utilizing FAM19A4, JAM3, and PAX1 gene methylation-specific primers and probes, along with blocking primers, to enhance detection sensitivity and specificity through multi-channel fluorescence and optimized PCR conditions
Implementation Method 3
A composition and kit utilizing FAM19A4, JAM3, and PAX1 gene methylation-specific primers and probes, along with blocking primers, to enhance detection sensitivity and specificity through multi-channel fluorescence and optimized PCR conditions
Data Source
AI summary
The invention discloses a composition and kit for early detection of high-grade cervical lesions and cervical cancer, wherein the composition for early detection of high-grade cervical lesions and cervical cancer includes methylation primers, a probe corresponding to methylated sites and methylation blocking primers for FAM19A4 gene; methylation primers, a probe corresponding to methylated sites and methylation blocking primers for JAM3 gene; methylation primers, a probe corresponding to methylated sites and methylation blocking primers for PAX1 gene; and 1 pair of primers and a probe corresponding to methylated sites for internal reference gene GAPDH. The methylated sites in FAM19A4, JAM3 and PAX1 genes are accurately detected using multiple multi-channel fluorescence and blocking techniques through accurate recognition between specific primers and probes and methylated sequences, full release of methylated templates under the action of multiple blocking primers and optimized special methylation DNA polymerase.